Linagliptin Krka

Linagliptin, the active ingredient in Linagliptin Krka, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, acting on the incretin pathway to regulate blood glucose.

- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels by enhancing insulin secretion and suppressing glucagon. - Type 2 diabetes mellitus (add‑on therapy): provides additional glycaemic control when combined with metformin or other oral agents. - Adjunct to diet and exercise: supports lifestyle measures aimed at achieving target HbA1c.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient cranial discomfort. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea or abdominal discomfort. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder. - Hepatic injury: jaundice or elevated liver enzymes. - Acute renal failure: sudden decline in kidney function. - Cardiovascular events: rare reports of heart failure exacerbation.

Linagliptin should be used with awareness of specific safety considerations.

- Renal impairment: assess kidney function before initiating therapy. - Hepatic impairment: monitor liver enzymes in patients with liver disease. - Concomitant sulfonylureas or insulin: adjust dose to reduce hypoglycaemia risk. - History of pancreatitis: avoid use or discontinue if symptoms recur. - Known hypersensitivity: do not use in patients with documented allergy to linagliptin. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Linagliptin may interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia; avoid combination without dose adjustment. - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce linagliptin exposure and efficacy.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin plasma levels. - Diuretics: may affect renal clearance, requiring renal function monitoring. - ACE inhibitors or ARBs: monitor blood pressure and renal function when used together. - Anticoagulants: observe for any changes in coagulation parameters.